1 admet prediction supplier across 1 states and provinces in 1 country. Profiles show capabilities, materials, certifications, and facility locations so you can compare shops and build a shortlist.
CuraGenAI designs disease-modifying small molecules for hard-to-treat diseases and accelerates target-to-lead discovery by combining generative AI, reinforcement learning, and ML model architectures with biology and structure-based validation. Its CureRX platform delivers synthesis-ready lead series to pharma and biotech partners, compressing target-to-lead discovery from years to weeks. Selected programs advance toward clinical translation through CuraGen Neuro Therapeutics, including a brain-directed ACAT1/SOAT1 program in glioblastoma.
de novo molecular designgenerative chemistrymulti-objective optimizationReinforcement learningsmall-molecule discoverystructure-based validationtarget definition and druggability assessment
Related capabilities
Other processes offered by the shops that list ADMET prediction.
